530 results on '"Rancati, Tiziana"'
Search Results
152. Breast Irradiation with Three Conformal Photon Fields for Patients with High Lung Involvement
153. REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer
154. Patterns in ano-rectal dose maps and the risk of late toxicity after prostate IMRT
155. In Reply to Loganadane et al
156. Genetic Variants Predict Optimal Timing of Radiotherapy to Reduce Side-effects in Breast Cancer Patients
157. Inter-observer variability in contouring the penile bulb on CT images for prostate cancer treatment planning
158. Supporting Patients With Untreated Prostate Cancer on Active Surveillance: What Causes an Increase in Anxiety During the First 10 Months?
159. External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort.
160. Abstract A032: miR-205 reconstitution sensitizes prostate cancer cells and xenografts to radiotherapy, through PKCϵ suppression
161. Machine Learning and Radiogenomics: Lessons Learned and Future Directions
162. Texture analysis of T1-w and T2-w MR images allows a quantitative evaluation of radiation-induced changes of internal obturator muscles after radiotherapy for prostate cancer
163. Metamodeling of late rectal bleeding in patients undergoing radiotherapy for prostate cancer.
164. Active surveillance in prostate cancer patients: Modeling upgrading and upsizing at 1 year rebiopsy.
165. Evaluation of Mediators Associated with the Inflammatory Response in Prostate Cancer Patients Undergoing Radiotherapy
166. Cytokine levels during prostate cancer radiotherapy
167. 1385: Beyond erectile dysfunction: time patterns of sexual health after radiotherapy for prostate cancer.
168. Understanding Urinary Toxicity after Radiotherapy for Prostate Cancer: First Steps Forward
169. Eleven-year Management of Prostate Cancer Patients on Active Surveillance: What have We Learned?
170. Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era
171. Predicting late fecal incontinence risk after RT for prostate cancer: External independent validation.
172. Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force
173. “What if…”: Decisional Regret in Patients who Discontinued Active Surveillance
174. Comment on “Objective assessment in digital images of skin erythema caused by radiotherapy” [Med. Phys. 42, 5568-5577 (2015)]
175. The REQUITE-AB study: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in breast cancer patients
176. Predicting toxicity in radiotherapy for prostate cancer
177. The REQUITE Project: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in cancer survivors.
178. Modeling severe late rectal bleeding: Results on a large pooled population of prostate cancer patients.
179. Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy
180. 2089: Development and validation of a risk model for local failure in pancreatic cancer after SBRT.
181. Multi-variable models predicting specific patient-reported acute urinary symptoms after radiotherapy for prostate cancer: Results of a cohort study
182. Embracing Phenomenological Approaches to Normal Tissue Complication Probability Modeling: A Question of Method
183. The REQUITE project: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side effects.
184. Modeling acute urinary toxicity after radiotherapy for prostate cancer.
185. Italian cultural adaptation of the Memorial Anxiety for Prostate Cancer scale for the population of men on active surveillance
186. Editorial Comment to Health‐related quality of life after carbon‐ion radiotherapy for prostate cancer: A 3‐year prospective study
187. Reply from Authors re: Laurence Klotz. Active Surveillance, Quality of Life, and Cancer-related Anxiety. Eur Urol 2013;64:37–9
188. Predictors of Health-related Quality of Life and Adjustment to Prostate Cancer During Active Surveillance
189. Impact of the radiotherapy technique on the correlation between dose–volume histograms of the bladder wall defined on MRI imaging and dose–volume/surface histograms in prostate cancer patients
190. Baseline-Status und Dosis auf den Bulbus penis als Prädiktoren für Impotenz ein Jahr nach Radiotherapie bei Prostatakrebs.
191. Correlation between surrogates of bladder dosimetry and dose–volume histograms of the bladder wall defined on MRI in prostate cancer radiotherapy
192. Increasing the risk of late rectal bleeding after high-dose radiotherapy for prostate cancer: The case of previous abdominal surgery. Results from a prospective trial
193. Centralized revision of diagnostic pathologic slides for prostate cancer patients on active surveillance: Is it just time- and resource-consuming?
194. Modeling fecal incontinence symptoms 6 years after high-dose radiation for prostate cancer: Clinical and dosimetric predictors.
195. Long-term biochemical control of prostate cancer after standard or hyper-fractionation: Evidence for different outcomes between low–intermediate and high risk patients
196. Inter-observer variability in contouring the penile bulb on CT images for prostate cancer treatment planning
197. Inclusion of clinical risk factors into NTCP modelling of late rectal toxicity after high dose radiotherapy for prostate cancer
198. Feasibility of safe ultra-high (EQD2>100 Gy) dose escalation on dominant intra-prostatic lesions (DILs) by Helical Tomotheraphy
199. 3D-planning in HDR brachytherapy of cervical cancer. Analysis of dose volume histograms and clinical correlations
200. miRNAs in tumor radiation response: bystanders or participants?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.